Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04392193
Other study ID # 18-009485
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 19, 2021
Est. completion date March 9, 2024

Study information

Verified date May 2024
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Researchers are gathering information on the safety and effectiveness of proton radiation therapy in reducing the number of ventricular tachycardia (VT) episodes in subjects who continue to experience VT despite treatment with an implantable cardioverter defibrillator (ICD) and undergoing a previous catheter ablation.


Description:

Proton therapy has been approved by the U.S. Food and Drug Administration (FDA) for cancer patients, including tumors in the heart, but not for treating heart rhythm disorders. The use of proton radiation therapy to treat heart rhythm disorders including VT and ventricular fibrillation (VF) is new and investigational; however, the FDA has approved proton therapy to treat abnormal rhythm disorders for this study. The development of a proton radiation therapy approach could be of substantial value in providing alternative therapy to either drug therapy or catheter-based ablation. With appropriate development, this therapy may be successful in the primary or secondary elimination of arrhythmias. Participants will be followed at 1 and 2 weeks, 1, 3, 6, 12 and 24-month intervals following treatment throughout the trial. Participant involvement will last approximately two years from the time of the proton radiation therapy procedure or until the last subject enrolled completes a 24 month follow-up.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date March 9, 2024
Est. primary completion date March 9, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Prior myocardial infarction, or non-ischemic disease, resulting in myocardial dysfunction 2. EF <50% 3. An implanted ICD device as secondary prevention for monomorphic VT/VF (MMVT/MMVF). This includes patients who receive a device for primary prevention and then have recurrent sustained monomorphic VT or VF. 4. Have failed a prior catheter-based ablation for VT/VF after device implantation or have a contraindication to repeat ablation and have failed reasonable drug options over the 9 months prior to consideration of particle therapy. 5. Repeat ablation from an epicardial venue in the absence of prior cardiac surgery, or where such an ablation is felt to be inappropriate in the view of the PI. 6. Electrocardiographic documentation of 2 additional episodes of recurrent, sustained monomorphic ventricular tachycardia (MMVT) and/or PVC induced VT or VF that are terminated by ATP or ICD shocks (by device interrogation) over the past 9 months, since the sentinel ablation (see criteria #4). Also included, incessant VT that does not fall within device parameters for activation of ATP or shock delivery or is refractory to medication titration. 7. Age <=80 years. Exclusion Criteria: 1. VT in the absence of cardiomyopathy. 2. Reversible causes of VT including thyroid disorders, acute alcohol intoxication, recent major surgical procedures, trauma, or VT clearly produced by recurrent ischemia. 3. Multiple (e.g.>3) clinical VT morphologies that are thought to originate from widely disparate RV or LV areas. 4. Recent cardiac events including MI, PCI, or valve or bypass surgery in the preceding 3 months, or anticipated in the next 3 months. 5. Hypertrophic obstructive cardiomyopathy (HOCM) >Class IV 6. Progressive Class IV angina, or Class IV CHF (including past, or planned heart transplantation). 7. Heritable arrhythmias or increased risk for torsade de pointes with Class I or III drugs. 8. Prior surgical interventions for VT such as an encircling ventriculotomy procedure. 9. Contraindication to appropriate anti-coagulation therapy after ablation. 10. Renal failure requiring dialysis. 11. Prior therapeutic radiation therapy to the left chest that would preclude safe ablation of the cardiac target in the judgement of the radiation oncologist. 12. Medical conditions limiting expected survival <1 year. 13. Women of child bearing potential (unless post-menopausal or surgically sterile) 14. Participation in any other clinical mortality trial (participation in other non-mortality trials should be reviewed with the clinical trial management center) 15. Unable to give informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Proton Particle Therapy
Proton therapy will be delivered in a single fraction using the Probeat-V system

Locations

Country Name City State
United States Mayo Clinic in Rochester Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Konstantinos Siontis

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mortality Total number of subject deaths 2 years
Primary Implantable Cardioverter Defibrillator (ICD) Shocks Total number of recurrent ICD shocks 2 years
Primary Recurrent Ventricular Tachycardia (VT) Total number of recurrent VT requiring repetitive antitachycardia pacing (ATP) device therapy 2 years
Primary Cardiac Arrest Total number of cardiac arrests 2 years
See also
  Status Clinical Trial Phase
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT02241252 - Using an iPhone ECG to Monitor the QT Interval on Dofetilide and Sotalol Patients N/A
Completed NCT01428778 - Berlin Beat of Running Study N/A
Completed NCT01626261 - Examination of Implant´s Safety in an Electronic and Magnetic Field Environment
Withdrawn NCT01359683 - Heart Rate Variability Changes During Cardiac Surgery And The Incidence Of Post-Operative Cardiac Arrhythmias N/A
Recruiting NCT04154982 - N-Acetylcysteine Protection Against Radiation Induced Cellular Damage Phase 2
Completed NCT04609683 - Measuring Hydration Levels of Healthy and Heart Failure Patients Before, During, and After an Electrophysiology (EP) Procedure N/A
Completed NCT04162249 - High Radiofrequency Power for Faster and Safer Pulmonary Veins Isolation - a Pilot Observational Study.
Withdrawn NCT05084391 - Phase I/II Randomized Study of Stereotactic Ablative Radiotherapy (SABR) Versus Standard of Care for Refractory Structural Cardiac Arrhythmias (SABR-HEART) Phase 1/Phase 2
Completed NCT03260244 - EnSite Precision Observational Study
Recruiting NCT04474418 - Psychometric Characterization of Patients With Cardiac Arrhythmias
Recruiting NCT03996954 - Validation of a Smartphone-based Recorder for Detection of Cardiac Arrhythmias N/A
Recruiting NCT05508880 - SIGIL: Signal Interpretation and Analysis In Real Life Cardiac Arrhythmias
Terminated NCT04552665 - Prospective Procedural Data Collection for Continuous Improvement of the KODEX - EPD™ System Performance.
Recruiting NCT06073509 - Atrial Fibrillation and Other Cardiac Arrhythmias and Diseases After Radiotherapy for Breast Cancer : Watch Your HeaRT
Completed NCT04463524 - Screening for Hearth Rhythm Disorders
Withdrawn NCT01394965 - Electrocardiographic Mapping and Imaging Phase 0
Completed NCT01672528 - Patient Reported Outcome Measures for Ablation of Cardiac Arrhythmias
Completed NCT02232204 - Sleep and Ventricular Arrhythmias Study Phase 2
Completed NCT05114382 - An Evaluation of the Safety and Performance of the CathVision Cube® System N/A